Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide

Breast Cancer Research and Treatment

Volumn 76, Issue 2, 2002, Pages 157-166

  Simões Wüst, A Paula ^a   Schürpf, Thomas ^a   Hall, Jonathan ^b   Stahel, Rolf A ^a   Zangemeister Wittke, Uwe ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antisense; Bcl 2 bcl xL; Breast cancer; Chemotherapy; Synergistic interaction

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; OLIGONUCLEOTIDE 4625; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL ASSAY; CELL STRAIN MCF 7; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0036830417     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020543004400     Document Type: Article

References (34)

1. Dickson RB, Lippman ME: Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds) CANCER - Principles and Practice of Oncology. Lippincott-Raven, Philadelphia, 1997, pp 1541-1616
2. Olie RA, Zangemeister-Wittke U: Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutical potential. Drug Resist Update 4: 9-15, 2001
3. Adams JM, Cory S: The bcl-2 protein family: Arbiters of cell survival. Science 281: 1322-1326, 1998
4. Kaufmann SH, Gores G: Apoptosis in cancer: Cause and cure. Bioessays 22: 1007-1017, 2000
5. NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O'Loughlin C, Daly C, Nunez G, Scanlon KJ, Clynes M: Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer 82: 368-376, 1999
6. Sierra A, Castellsague X, Escobedo A, Lloveras B, Garcia-Ramirez M, Moreno A, Fabra: Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer. Int J Cancer 89: 142-147, 2000
7. Perillo B, Sasso A, Abbondanza C, Palumbo G: 17β-estradiol inhibits apoptosis in MCF7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901, 2000
8. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, Recant WM: Overexpression of bcl-xL protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 3: 230-237, 1997
9. Simões-Wüst AP, Olie RA, Gautschi O, Leech SH, Häner R, Hall J, Fabbro D, Stahel RA, Zangemeister-Wittke U: Bcl-xL antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 87: 582-590, 2000
10. Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Nishimura Y, Imamura M: Role of bcl-2 family proteins (bax, bcl-2 and bcl-xL) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 35: 1374-1380, 1999
11. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA, Wyche JH: Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from bcl-2 to bcl-xL. Cancer Res 561: 621-628, 1996
12. Arriola EL, Rodriguez LA, Hickman JA, Chresta CM: Bcl-2 overexpression results in reciprocal downregulation of bcl-xL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 18: 1457-1464, 1999
13. Zangemeister-Wittke U, Leech SH, Olie RA, Simões-Wüst AP, Gautschi O, Luedke GH, Natt F, Häner R, Martin P, Hall J, Nalin CM, Stahel RA: A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 6: 2547-2555, 2000
14. Freier SM, Altmann KH: The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemically-modified DNA:RNA duplexes. Nucl Acids Res 25: 4429-4443, 1997
15. Olie RA, Hall J, Natt F, Stahel R, Zangemeister-Wittke U: Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide. Biochim Biophys Acta 1576: 101-109, 2002
16. Gautschi O, Tschopp S, Leech SH, Olie RA, Simões-Wüst AP, Baumann B, Haener R, Hall J, Stahel R, Zangemeister-Wittke U: Potent antitumor activity of a bcl-2/bcl-xL bispecific antisense oligonucleotide against cell lines from solid tumors of diverse histological origin. J Natl Cancer Inst 93: 463-471, 2000
17. Olie RA, Hafner C, Küttel R, Sigrist B, Willers J, Dummer R, Hall J, Stahel R, Zangemeister-Wittke U: Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in malignant melanoma cells of different clinical stages. J Invest Dermatol 1198: 505-512, 2002
18. Ziegler A, Simões-Wüst AP, Zangemeister-Wittke U: Optimizing the efficacy of antisense oligodeoxynucleotides targeting inhibitors of apoptosis. Meth Enzymol 314: 477-490, 1999
19. De Mesmaeker A, Häner R, Martin P, Moser HE: Antisense oligonucleotides. Acc Chem Res 28: 366-374, 1999
20. Martin P: Ein neuer zugang zu 2′-O-alkylribonucleosiden und eigenschaften deren oligonucleotide. Sep Helv Chim Acta 78: 486-504, 1995
21. Leech SH, Olie RA, Gautschi O, Simões-Wüst AP, Tschopp S, Häner R, Hall J, Stahel RA, Zangemeister-Wittke U: Induction of apoptosis in lung-cancer cells by bcl-xL antisense treatment. Int J Cancer 86: 570-576, 2000
22. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984
23. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA: Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small cell lung cancer cell lines. Br J Cancer 78: 1035-1042, 1998
24. Leist M, Jäättelä M: Four deaths and a funeral: From caspases to alternative mechanisms. Nature Rev 2: 2-10, 2001
25. Fornier M, Munster P, Seidman A: Update on the management of advanced breast cancer. Oncology 13: 647-658, 1999
26. Kaufmann SH, Earnshaw W: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000
27. Chan T, Hermeking H, Lengauer C, Kinzler K, Vogelstein B: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999
28. Lopes-de-Menezes D, Hudon N, McIntosh N, Mayer L: Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6:2891-2902, 2000
29. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME: Synergistic chemosensitization and inhibition of progression to androgen independence by antisense bcl-2 oligonucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 91: 846-850, 2001
30. Klasa R, Bally M, Ng R, Goldie J, Gascoyne R, Wong F: Eradication of human non-Hodgkin's lymphoma in SCID mice by bcl-2 antisense oligonucleotides combined with lowdose cyclophosphamide. Clin Cancer Res 6: 2492-2500, 2000
31. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein C: Bcl-xL in prostate cancer cells: Effects of overexpression and downregulation on chemosensitivity. Cancer Res 60: 6052-6060, 2000
32. Miyake H, Monia BP, Gleave ME: Inhibition of progression to androgen-independence by combined adjuvant treatment bcl-xL and antisense bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 86: 855-862, 2000
33. Fulda S, Kufer M, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin K: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865-5877, 2001
34. Photiou A, Shah P, Leong L, Moss J, Retsas S: In vitro synergy of paclitaxel (taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 33: 463-470, 1997